J Fraser Wright, PhD
Dr. Wright received his PhD in 1989 from the University of Toronto (Biochemistry) for studies
characterizing the interaction of complement with IgM, and completed post-doctoral studies at INSERM
/ CENG Grenoble, France in molecular immunology focused on antigen processing and presentation. He
was awarded a CRCS/ MRC Scholarship, gaining faculty appointment at the University of Toronto. In
1996 he joined industry as a Scientist at Pasteur Sanofi, contributing there to the development of
vaccines and cancer immunotherapies, and subsequently as Director of Development and Clinical
Manufacturing at Avigen, a gene therapy company that pioneered AAV-based investigational gene
therapies for hemophilia and Parkinson?s disease. In 2004 he returned to academia, establishing and
directing the Clinical Vector Facility at the Center for Cellular and Molecular Therapeutics at Children?s
Hospital of Philadelphia, and gaining faculty appointment at the University of Pennsylvania Perelman
School of Medicine as professor of Pathology and Laboratory Medicine. Dr. Wright has contributed to
several clinical development programs in gene therapy, including for Luxturna and Kymriah, the first
gene therapies for a genetic (RPE65 deficiency) and non-genetic (CAR-T immunotherapy) disease,
respectively, approved in the United States, and for the first gene therapy clinical trial that delivered an
AAV-vectorized monoclonal antibody to human subjects for HIV passive immunity. He is a Co-founder of
Spark Therapeutics, serving there and subsequently at Axovant as Chief Technology Officer. In 2019 Dr.
Wright joined Stanford University as Professor of Pediatrics at The Center for Definitive and Curative
Medicine (CDCM). His research program aims to address key immunological barriers to gene therapy
through innovative approaches to viral vector design and generation, and to develop vectorized
antibodies for serious human diseases.


2020-21 Courses

Stanford Advisees

Footer Links:

Home | Stanford Medicine

Latest information on COVID-19

Stanford Medicine is closely monitoring the COVID-19 pandemic. Get the latest news on COVID-19 testing, treatment, tracking data, and medical research.

Racism and discrimination are direct affronts to Stanford Medicine?s values. Read our leaders? pledge on racial equity.

A leader in the biomedical revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies.

Analyzing a national cancer database, Stanford Medicine researchers find a bump in diagnoses at 65, suggesting that many wait for Medicare to kick in before they seek care.

Our scientists have launched dozens of research projects as part of the global response to COVID-19. Some aim to prevent, diagnose and treat the disease; others aim to understand how it spreads and how people?s immune systems respond to it.

A Stanford Medicine team offered guidance in crafting a COVID-19 response for the Oglala Lakota Nation.

Medical students recently learned where they would be heading for their residencies.

Sharon Hampton is focusing on patient equity as a nursing leader at Stanford Health Care. Getting to know patients and staff is key, she says.

Stanford Medicine Resources: